Collection |

Cancer immunotherapies

Cancer therapies that target multiple immune pathways take advantage of synergistic killing and decrease the risk of relapse.

This Collection is updated when relevant new content is published. Content appears in reverse chronological order. See all Collections from Nature Biomedical Engineering.

Research

  • Nature Biomedical Engineering | Article

    The physiological degradation of programmed-death ligand 1 is reduced by the palmitoylation of its intracellular domain, and this process can be inhibited to promote T-cell immunity against tumours.

    • Han Yao
    • , Jiang Lan
    • , Chushu Li
    • , Hubing Shi
    • , Jean-Philippe Brosseau
    • , Huanbin Wang
    • , Haojie Lu
    • , Caiyun Fang
    • , Yao Zhang
    • , Lunxi Liang
    • , Xiaolin Zhou
    • , Chaojun Wang
    • , Yu Xue
    • , Yun Cui
    •  &  Jie Xu
  • Nature Biomedical Engineering | Article

    The systemic administration of haematopoietic stem cells conjugated to anti-PD-1-decorated platelets in leukaemic mice promotes the delivery of the checkpoint inhibitor to the bone marrow and suppresses the growth and recurrence of leukaemia.

    • Quanyin Hu
    • , Wujin Sun
    • , Jinqiang Wang
    • , Huitong Ruan
    • , Xudong Zhang
    • , Yanqi Ye
    • , Song Shen
    • , Chao Wang
    • , Weiyue Lu
    • , Ke Cheng
    • , Gianpietro Dotti
    • , Joshua F. Zeidner
    • , Jun Wang
    •  &  Zhen Gu
  • Nature Biomedical Engineering | Article

    The combination of systemic immune checkpoint inhibition with local administration of a hydrogel containing the enzyme catalase, a radioisotope and an immunostimulatory agent promotes effective antitumour immune responses in mice models.

    • Yu Chao
    • , Ligeng Xu
    • , Chao Liang
    • , Liangzhu Feng
    • , Jun Xu
    • , Ziliang Dong
    • , Longlong Tian
    • , Xuan Yi
    • , Kai Yang
    •  &  Zhuang Liu
  • Nature Biomedical Engineering | Article

    A supramolecule that inhibits the colony stimulating factor 1 and SIRPα receptors on macrophages significantly enhances antitumour and antimetastatic efficacies in two aggressive animal models of melanoma and breast cancer.

    • Ashish Kulkarni
    • , Vineethkrishna Chandrasekar
    • , Siva Kumar Natarajan
    • , Anujan Ramesh
    • , Prithvi Pandey
    • , Jayashree Nirgud
    • , Harshangda Bhatnagar
    • , Driti Ashok
    • , Amrendra Kumar Ajay
    •  &  Shiladitya Sengupta
  • Nature Biomedical Engineering | Review Article

    This Review discusses the manufacturing of cell products for clinically advanced cell therapies, and highlights potential manufacturing bottlenecks and solutions towards the cost-effective commercialization of the therapies.

    • Ayesha Aijaz
    • , Matthew Li
    • , David Smith
    • , Danika Khong
    • , Courtney LeBlon
    • , Owen S. Fenton
    • , Ronke M. Olabisi
    • , Steven Libutti
    • , Jay Tischfield
    • , Marcela V. Maus
    • , Robert Deans
    • , Rita N. Barcia
    • , Daniel G. Anderson
    • , Jerome Ritz
    • , Robert Preti
    •  &  Biju Parekkadan
  • Nature Biomedical Engineering | Article

    β-Cyclodextrin nanoparticles carrying an antagonist of the toll-like receptors TLR7 and TLR8 drive the M1 phenotype in tumour-associated macrophages and improve immunotherapy response rates in tumour mouse models when used with checkpoint blockade.

    • Christopher B. Rodell
    • , Sean P. Arlauckas
    • , Michael F. Cuccarese
    • , Christopher S. Garris
    • , Ran Li
    • , Maaz S. Ahmed
    • , Rainer H. Kohler
    • , Mikael J. Pittet
    •  &  Ralph Weissleder

News & Comment

  • Nature Biomedical Engineering | News & Views

    Enhanced lysosomal degradation of the transmembrane protein programmed cell-death protein-1 ligand in tumour cells, enabled by blocking the protein’s post-translational lipid modification, promotes T-cell-mediated suppression of tumour growth in mice.

    • Stephane Lefrancois
  • Nature Biomedical Engineering | News & Views

    The coupling of blood platelets bearing anti-programmed cell death protein 1 antibodies to haematopoietic stem cells enables delivery of checkpoint-blockade therapy to bone marrow to promote T-cell-mediated control of leukaemia in mice.

    • Martina Seiffert
  • Nature Biomedical Engineering | Editorial

    Cancer therapies that target multiple biological pathways take advantage of synergistic killing, and decrease the risk of relapse.

  • Nature Biomedical Engineering | News & Views

    Intratumoral injection of a hydrogel impregnated with radioisotope-labelled catalase and an immunostimulant, along with systemic immune checkpoint blockade, inhibits tumour growth in mouse models of localized cancer and metastatic cancer.

    • Catherine S. Spina
    •  &  Charles G. Drake